Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT06179069
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- NCT06179069 ↗
- Recruiting
- Zai Lab (Shanghai) Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- SCLC
- Interventions
- ZL-1310; Atezolizumab; Carboplatin
- Arms
- Dose Escalation: Part 1A · Experimental
- Dose Expansion: Part 1B · Experimental
- Dose Escalation: Part 1C · Experimental
- Dose Expansion: Arm 1 (Part 2) · Experimental
- Dose Expansion: Arm 2 (Part 2) · Experimental
- Dose Extension: Arm 1 (Part 2) · Experimental
- Doublet Dose Optimization: Arm 1 (Part 3A) · Experimental
- Doublet Dose Optimization: Arm 2 (Part 3A) · Experimental
- Triplet Dose Optimization: Arm 1 (Part 4A) · Experimental
- Triplet Dose Optimization: Arm 2 (Part 4A) · Experimental
- Dose Extension: Part 2-1 · Experimental
- Doublet Dose Extension: Part 3B · Experimental
- Triplet Dose Extension: Part 4B · Experimental
- Enrollment
- 339 (estimated)
- Primary outcomes
- Incidence of Dose Limiting Toxicities of ZL-1310 as a single agent (Part 1A), in combination with Atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)
- Incidence of Treatment Emergent Adverse-Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)
- Incidence of Serious Adverse Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)
- Incidence of Treatment Emergent Adverse Events of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3) and in combination with atezolizumab and carboplatin (Part 4)
- Incidence of Serious Adverse-Events (SAEs) of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)
- Antitumor activity per RECIST v1.1 by investigator's assessment of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)
- Objective response rate (ORR) per RECIST v1.1 of ZL-1310 as a single agent (Part 2) and in combination with atezolizumab and carboplatin (Part 4)
- Disease control rate (DCR) per RECIST v1.1 of ZL-1310 in combination with atezolizumab
- Sponsor
- Zai Lab (Shanghai) Co., Ltd. with Zai Lab (US) LLC
- Start
- Jan 23, 2024
- Primary completion
- May 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06179069 · updated Oct 16, 2026